GANX earnings analysis
What we found in GANX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 diluted EPS of $(0.11) improved from $(0.13) in Q1 2026 and $(0.19) in the prior-year quarter, although the supplied 10-Q extract does not include revenue, margins, cash flow, balance-sheet, or segment data. Disclosure controls were assessed as effective as of June 30, 2026, with no material changes in internal control reported. The principal newly disclosed negative is litigation seeking more than $3.1 million, with the motion to dismiss pending.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS improved year over year
- Diluted EPS was $(0.11) in Q2 2026, improving from $(0.13) in Q1 2026 and $(0.19) in Q2 2025; the result also exceeded the $(0.15) consensus estimate.
- Disclosure controls deemed effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Pending litigation exceeds $3.1 million
- The amended complaint seeks monetary damages in excess of $3.1 million, plus pre- and post-judgment interest. The defendants’ April 28, 2026 motion to dismiss is fully briefed and pending adjudication.
- No updated risk-factor detail
- The company states that its risk factors remain those described in the 10-K for the year ended December 31, 2025, filed March 26, 2026; no specific new or amended risk factor was identified in the supplied 10-Q text.
- Controls have inherent limitations
- The company acknowledges that its control systems provide only reasonable, rather than absolute, assurance and cannot ensure that errors, fraud, or all control issues will be detected.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.11
What they said about what is next.
No quantitative financial guidance or MD&A outlook was provided in the supplied filing extract. Operational milestones cited in prior company disclosures include Phase 2 initiation for rexaceract expected in Q3 2026 and Phase 1b final results expected in Q4 2026.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 11, 2026
- Gain Therapeutics reported a net loss of $5.6 million for Q1 2026, up from a loss of $4.5 million in Q1 2025. The company continues to show no revenue generation, reflecting ongoing early-stage development challenges.…
- 10-K · March 26, 2026
- Gain Therapeutics’ 10-K emphasizes clinical progress for lead oral small molecule GT-02287 (Parkinson’s) and the company’s Magellan™ discovery platform as the core strategic moat. The filing documents positive Phase 1…
- 10-Q · November 12, 2025
- Gain Therapeutics reported a Q3 2025 net loss per share of $0.15 (three months ended September 30, 2025), roughly in line with consensus and slightly improved versus Q3 2024 ($0.17). The company has $8.8 million of cash…
- 10-Q · August 12, 2025
- Gain Therapeutics reported a narrower quarterly net loss of $5.81 million (EPS -$0.19) for the three months ended June 30, 2025 versus a loss of $8.14 million (EPS -$0.42) in the year-ago quarter, driven by lower R&D…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GANX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever